Publication

Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: results from the myeloma X (intensive) trial.

Ashcroft, J
; 
Cairns, D
; 
Williams, C
; 
Hockaday, A
; 
Cavenagh, J
; 
Snowden, J
; 
Parrish, C
; 
Yong, K
; 
Cavet, James
; 
Hunter, H
... show 8 more
Citations
Altmetric:
Abstract
Authors
Ashcroft, J
Cairns, D
Williams, C
Hockaday, A
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Pratt, G
Chown, S
Heartin, E
O'Connor, S
Brown, J
Morris, C
Cook, G
Affiliation
Mid-Yorkshire Hospitals NHS Trust/Univeristy of Leeds, Wakefield
Description
Date
2015
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: results from the myeloma X (intensive) trial. 2015, 126 (23): Blood
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/603984
Embedded videos